Is GMAB or GNLX more undervalued in 2026?

CirclFi compares Genmab A/S (GMAB) and Genelux Corporation (GNLX) using 13 institutional-grade valuation models. GMAB has a Quality of Company score of 6.7/10 while GNLX scores 5.1/10.

Which is a better buy — GMAB or GNLX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GMAB and GNLX valuations compare?

GMAB at $26.33 and GNLX at $3.05 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GMAB vs GNLX Valuation Comparison 2026 — Intrinsic Value Analysis

GMAB

Pharmaceutical Preparations

Genmab A/S

Quality

6.7

out of 10

Value Trap

—

Price

$26.33

Last close

Models

13/13

Active

GNLX

Pharmaceutical Preparations

Genelux Corporation

Quality

5.1

out of 10

Value Trap

LOW

Price

$3.05

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	GMAB Fair Value	GMAB Upside	GNLX Fair Value	GNLX Upside
Bayesian DCF	Intrinsic	$29.52	+12.1%	$0.87	-71.4%
Earnings Power Value	Intrinsic	$22.32	-15.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$59.28	+125.2%	$0.33	-89.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GMAB vs GNLX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GMAB vs GNLX — Which Stock Is More Undervalued?

GMAB scores higher with a 6.7/10 quality rating vs GNLX's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Genmab A/S (GMAB) and Genelux Corporation (GNLX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GMAB currently trades at $26.33 with a QOC of 6.7/10, while GNLX trades at $3.05 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).